Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Atypical Hyperplasia|Breast Lobular Carcinoma in Situ|Breast Atypical Lobular Hyperplasia
Interventions: DRUG: Tamoxifen|DRUG: Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day|DRUG: Placebo
Sponsor: Amy C. Degnim
Collaborators: National Cancer Institute (NCI)